WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2002028904) HUMAN ANTI-CD40 ANTIBODIES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2002/028904    International Application No.:    PCT/US2001/030857
Publication Date: 11.04.2002 International Filing Date: 02.10.2001
Chapter 2 Demand Filed:    28.02.2002    
IPC:
C07K 16/28 (2006.01)
Applicants: CHIRON CORPORATION [US/US]; 4560 Horton Street Emeryville, CA 94608 (US) (For All Designated States Except US).
CHU, Keting [US/US]; (US) (For US Only).
WANG, Changyu [CN/US]; (US) (For US Only).
YOSHIHARA, Corrine [US/US]; (US) (For US Only).
DONNELLY, John, J. [US/US]; (US) (For US Only)
Inventors: CHU, Keting; (US).
WANG, Changyu; (US).
YOSHIHARA, Corrine; (US).
DONNELLY, John, J.; (US)
Agent: ALEXANDER, Lisa; Chiron Corporation 4560 Horton Street Emeryville, CA 94608-2916 (US)
Priority Data:
60/237,556 02.10.2000 US
Title (EN) HUMAN ANTI-CD40 ANTIBODIES
(FR) ANTICORPS HUMAINS DIRIGES CONTRE CD40
Abstract: front page image
(EN)Human antibodies capable of binding CD40 are disclosed, wherein the antibodies act as antagonists of CD40-directed activities of B cells, but have no or minimal ability to induce B cell proliferation. The antibodies are useful for treating diseases mediated by CD40-expressing cells, such as those diseases characterized by B cell activation, as well as cancer of B-cell lineage, including Non-Hodgkin's Lymphoma.
(FR)L'invention concerne des anticorps capables de se lier à CD40. Ces anticorps revêtent la fonction d'antagonistes des activités dirigées par CD40 des cellules B, mais leur capacité d'induire la prolifération des cellules B est nulle ou minimale. Lesdits anticorps sont utiles pour traiter des maladies induites par les cellules exprimant CD40, telles que les maladies caractérisées par l'activation des cellules B, ainsi que le cancer associé aux cellules B, y compris le lymphome non hodgkinien.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)